Clinical trials: Food IgE-mediated Allergy
Cow Milk Allergy
Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins
The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in…
- Trial name
- NCT03557671
- Testing
- rice formula
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 72 people
- Sponsor
- United Pharmaceuticals
IgE-Mediated Cow Milk Allergy
Evaluation of the Tolerance of a New Formula Based on Hydrolyzed Rice Proteins in Children With Cow's Milk Allergy
The goal of this clinical trial is to see if a new formula based on hydrolysed rice proteins (Rice formula) is well tolerated by infants and young children with cow's milk allergy.
- Trial name
- NCT07197814
- Testing
- Rice formula (New formula based on hydrolysed rice proteins)
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Health and Happiness Research Limited
Food Hypersensitivity, Anaphylaxis
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel).
- Trial name
- NCT07027163
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
IgE-Mediated Food Allergy, Peanut Allergy
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin…
- Conditions
- IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
- Trial name
- NCT07768371
- Testing
- Remibrutinib
- Where
- 18 sites in United States
- Volunteers
- 576 people
- Sponsor
- Novartis Pharmaceuticals
Food Allergy
Use of Hypoallergenic (H.A.) Cereals in Children With Diagnosed Allergy to Wheat
The investigators plan to launch a Specific Oral Tolerance Induction (SOTI) pilot study in order to assess the efficacy and the safety of hypoallergenic (H.A.) wheat cereals, for children with allergy to wheat.
- Trial name
- NCT01332084
- Testing
- HA wheat cereals
- Where
- 2 sites in Switzerland
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Food Allergy
Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy
The objectives of this study are to evaluate the safety and efficacy of Viaskin Milk after 12 months of epicutaneous immunotherapy (EPIT) treatment, for desensitizing IgE-mediated cow's milk allergic children and to assess the…
- Trial name
- MILES (NCT02223182)
- Testing
- Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg
- Where
- 17 sites in United States, Canada
- Volunteers
- 198 people
- Sponsor
- DBV Technologies
Cow's Milk Allergy
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
Study to assess the diagnostic accuracy (sensitivity, specificity, positive and negative predictive value) of DBV1605 for the diagnosis of non-Immunoglobulin E (IgE) mediated cow's milk allergy (CMA) in children with symptoms…
- Trial name
- APTITUDE (NCT04492683)
- Testing
- DBV1605
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- DBV Technologies
Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy.
- Trial name
- NCT06369467
- Testing
- linvoseltamab, dupilumab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Regeneron Pharmaceuticals
Food Allergy
Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab
This is an expanded access program of dupilumab. The objective of the program is to provide continued dupilumab to adult participants with severe IgE-mediated food allergy who were previously treated with a short course of…
- Trial name
- NCT06631677
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Cow's Milk Allergy
Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.
The aim of this interventional study is to assess the hypoallergenicity of a new formula in infants having a cow milk allergy (CMA), whatever the type of CMA, meaning in both IgE-mediated and non-IgE-mediated CMA patients.
- Trial name
- MERLIN (NCT06481280)
- Testing
- Test Formula
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 70 people
- Sponsor
- United Pharmaceuticals
Ig-E Mediated Food Allergy
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal…
- Trial name
- NCT07220811
- Testing
- RPT904
- Where
- 37 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
- Conditions
- IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy, IgE-Mediated Cow Milk Allergy
- Trial name
- NCT07408869
- Testing
- Cizutamig
- Where
- Australia
- Sponsor
- Candid Therapeutics
Peanut Allergy
Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous…
- Trial name
- PEPITES (NCT02636699)
- Testing
- Viaskin Peanut 250mcg
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 500 people
- Sponsor
- DBV Technologies